Last updated on May 2018

Efficacy and Safety of Sotagliflozin Versus Glimepiride and Placebo in Subjects With Type 2 Diabetes Mellitus That Are Taking Metformin Monotherapy


Brief description of study

Primary Objective:

To demonstrate the non-inferiority of sotagliflozin dose 1 compared to glimepiride on HbA1c (glycosylated A1c) reduction in patients with T2D (type 2 diabetes) who have inadequate glycemic control with metformin.

Secondary Objectives:

To demonstrate the superiority of sotagliflozin dose 1 compared to glimepiride on change in body weight, SBP (systolic blood pressure) in patients with baseline SBP 130 mmHg, SBP in all patients, and proportion of patients with at least 1 documented symptomatic hypoglycemic event (70 mg/dL).

  • To demonstrate the superiority of sotagliflozin dose 1 compared to placebo on change in HbA1c, body weight, SBP (systolic blood pressure) in patients with baseline SBP 130 mmHg, SBP in all patients.
  • To demonstrate the superiority of sotagliflozin dose 2 compared to placebo on change in HbA1c.
  • To demonstrate the non-inferiority of sotagliflozin dose 2 compared to glimepiride on change in HbA1c.
  • To demonstrate the superiority of sotagliflozin dose 1 compared to glimepiride on change in HbA1c.
  • To evaluate the safety and tolerability of sotagliflozin compared to glimepiride and placebo.

Detailed Study Description

Up to 58 weeks, including a Screening Period consisting of a Screening phase of up to 2 weeks, a 2-week single-blind placebo Run-in phase, a 52-week double-blind Treatment Period, and a 2-week post-treatment Follow-up period to collect safety information

Clinical Study Identifier: NCT03332771

Contact Investigators or Research Sites near you

Start Over

For site information, send an ...

Investigational Site Number 8407121
Ocoee, FL United States
  Connect »